证券代码：002393 证券简称：力生制药 公告编号：2025-049 天津力生制药股份有限公司 第七届董事会第五十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年08月13日以书面方式 发出召开第七届董事会第五十二次会议的通知，会议于2025年08月20日以通讯表决方式召 开。会议应参加的董事9名，实际参加的董事9名。符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于2025年半年度报 告全文及摘要的议案》； 2025 年半年度报告及摘要详见巨潮资讯网（www.cninfo.com.cn）、中国证券报和证券 时报。 2、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于2025年半年度募 集资金存放与实际使用专项报告的议案》； 公 司 独 立 董 事 专 门 会 议 对 本 议 案 发 表 了 意 见 ， 具 体 内 容 详 见 巨 潮 资 讯 网 （www.c ...

天津力生制药股份有限公司 2025 年半年度报告全文 天津力生制药股份有限公司 2025 年半年度报告 国家医疗体制改革持续深化，实施带量采购、一致性评价、医保控费、两 票制、安全环保升级等政策，给公司经营发展带来挑战，对药品研发、生 产、销售产生较大影响。 （二）研发及转型风险 2025 年 8 月 天津力生制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个 别和连带的法律责任。 公司负责人张平、主管会计工作负责人王家颖及会计机构负责人(会计主 管人员)高峻声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 （一）行业政策变化风险 公司致力于通过研发创新促进公司的转型升级，由于医药行业新品研发周 期长、投入大、不确定性强，公司会面临研发不成功或研发效果不及预期的 风险。 （三）生产要素成本不断上涨的风险 ...

Group 1 - A total of 98 stocks have experienced consecutive increases for 5 trading days or more as of August 19 [1] - COFCO Sugar has seen a continuous rise for 12 trading days, while Lifespring Pharmaceutical, Junting Hotel, Rongchang Bio, and Yunzuka Technology have risen for 8 trading days [1] - During the consecutive rise period, Haineng Technology achieved a cumulative increase of 90.23%, and Gobika recorded a cumulative increase of 87.60% [1]

力生制药最新一期业绩显示，截至2025一季报，公司营业总收入3.70亿元、同比增长1.37%，归属净利 润5527.53万元，同比减少6.56%，扣非净利润5331.08万元，同比减少9.45%，流动比率4.334、速动比率 4.019、资产负债率16.39%。 金融界消息 截至2025年8月15日收盘，力生制药（002393）报收于25.29元，上涨1.93%，换手率 6.31%，成交量15.80万手，成交金额3.96亿元。 资金流向方面，今日主力资金净流入1462.33万元，占比成交额3.7%。其中，超大单净流入621.52万 元、占成交额1.57%，大单净流入840.81万元、占成交额2.13%，中单净流出流入1317.28万元、占成交 额3.33%，小单净流出2779.61万元、占成交额7.03%。 来源：金融界 天眼查商业履历信息显示，天津力生制药股份有限公司，成立于1981年，位于天津市，是一家以从事医 药制造业为主的企业。企业注册资本25794.2988万人民币，实缴资本25770.49万人民币。公司法定代表 人为张平。 通过天眼查大数据分析，天津力生制药股份有限公司共对外投资了12家企业，参与 ...

Group 1 - In January 2025, nearly 500 listed companies in the A-share market announced share buybacks, with a total buyback amount exceeding 18 billion yuan, surpassing the same period last year [1] - Major industry leaders are actively participating in the buyback trend, with 38 companies implementing buybacks exceeding 100 million yuan in January 2025 [2] - Kweichow Moutai leads the buyback efforts with approximately 1 billion yuan in buybacks, marking its first buyback plan in 23 years [2][3] Group 2 - China State Construction also engaged in buybacks, with an amount of 887 million yuan aimed at optimizing its capital structure [3] - Muyuan Foods announced a buyback plan of 3 to 4 billion yuan, having repurchased shares worth 1.25 billion yuan by the end of January 2025 [3] - The recent policy adjustments regarding buyback loans have stimulated market confidence, leading to over 100 companies disclosing buyback plans since the beginning of 2025 [4] Group 3 - Tianqi Materials reported a buyback of 6.524 million shares for a total of approximately 121 million yuan, funded by both its own resources and a special loan of 180 million yuan from CITIC Bank [4] - Zhongheng Group plans to repurchase shares worth 300 to 500 million yuan, supported by a loan commitment of up to 450 million yuan from Bank of Communications [5] - Shunfa Hengye intends to use its own funds and special loans for a buyback plan of 250 to 500 million yuan, with a loan commitment of up to 450 million yuan from China Construction Bank [5]

力生制药最新一期业绩显示，截至2025一季报，公司营业总收入3.70亿元、同比增长1.37%，归属净利 润5527.53万元，同比减少6.56%，扣非净利润5331.08万元，同比减少9.45%，流动比率4.334、速动比率 4.019、资产负债率16.39%。 天眼查商业履历信息显示，天津力生制药股份有限公司，成立于1981年，位于天津市，是一家以从事医 药制造业为主的企业。企业注册资本25794.2988万人民币，实缴资本25770.49万人民币。公司法定代表 人为张平。 资金流向方面，今日主力资金净流出2979.00万元，占比成交额12.62%。其中，超大单净流出2170.48万 元、占成交额9.2%，大单净流出808.52万元、占成交额3.43%，中单净流出流入1577.25万元、占成交额 6.68%，小单净流入1401.76万元、占成交额5.94%。 通过天眼查大数据分析，天津力生制药股份有限公司共对外投资了12家企业，参与招投标项目5000次， 知识产权方面有商标信息57条，专利信息80条，此外企业还拥有行政许可232个。 金融界消息 截至2025年8月11日收盘，力生制药（002393）报收于2 ...

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]

Group 1 - The core viewpoint emphasizes that the investment value in innovative drugs is not a short-term pulse but a long-term industrial dividend, driven by technological breakthroughs, policy support, and capital recognition [1] - The National Index for Hong Kong Innovative Drugs and the China Securities Innovative Drug Industry Index have achieved significant year-to-date gains of 106.7% and 32.3% respectively as of July 31 [1] - The innovative drug industry in China has transformed from a "follower" to a "leader" over the past decade, with domestic innovations like IO dual antibodies and ADC drugs leading international trends [1][9] Group 2 - The recent adjustment of the Hong Kong Innovative Drug ETF (159567) to exclude CXO companies and increase sample adjustment frequency to quarterly aims to enhance the index's focus on core innovative drug enterprises [4] - The index now primarily includes biotech companies that directly lead drug development and hold core patents, reflecting their competitive products and advancements [4] - The adjustment is expected to improve the index's sensitivity to emerging growth forces within the innovative drug sector [4] Group 3 - The innovative drug industry is currently experiencing a "golden development period" supported by favorable policies, including a strategic goal to create a globally competitive innovation ecosystem [6][5] - Multiple government agencies have introduced supportive measures to optimize approval processes and facilitate financing for biotech companies, enhancing the overall industry environment [6][7] - By 2024, the expenditure on innovative drugs from the medical insurance fund is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4 - The innovative drug sector is expected to see significant growth due to an aging population, with projections indicating that by the end of 2024, 15.6% of the population will be over 65 years old, leading to increased demand for innovative treatments [9] - The supply side is characterized by high technical barriers and a long development cycle, making quality innovative drugs relatively scarce and valuable [9][10] - China's innovative drugs currently account for less than 10% of the pharmaceutical market, indicating substantial room for growth compared to other G20 countries [10] Group 5 - The Hong Kong Innovative Drug ETF has achieved a year-to-date increase of 106.7%, leading the Hong Kong pharmaceutical sector [11] - The ETF focuses on biotech and pharmaceutical companies that are core to innovative drug development, ensuring high purity and precision in capturing industry growth [11] - The upcoming split of the Hong Kong Innovative Drug ETF on August 11 signifies the beginning of a long-term investment opportunity in the innovative drug sector [12]

Core Viewpoint - The investment value of innovative drugs is not a short-term pulse but a long-term industrial dividend, with optimal solutions for sharing this dividend through index tools in golden tracks [1] Group 1: Performance of Innovative Drug Indices - Since July, the National Index for Hong Kong Stock Connect Innovative Drugs and the China Securities Innovative Drug Industry Index have reached new highs, with year-to-date increases of 106.7% and 32.3% respectively as of July 31 [2] - The impressive performance of these indices reflects a decade-long transformation of China's innovative drug industry from "follower" to "leader" [2] - Recent inflows into ETFs tracking innovative drug indices have been significant, with a net inflow of 4.26 billion yuan from August 4 to August 8 and over 16 billion yuan since June [2] Group 2: Index Adjustments and Sensitivity - The recent upgrade of the Hong Kong Stock Innovative Drug Index aims to enhance its focus by excluding CXO companies and increasing adjustment frequency from semi-annual to quarterly, effective August 12 [3][4] - This adjustment allows the index to better capture the core drivers of the innovative drug industry, focusing on pharmaceutical companies that lead drug development and hold key patents [3] - The increased adjustment frequency enhances the index's sensitivity, enabling it to quickly identify emerging growth companies in a rapidly evolving market [4] Group 3: Policy Support for Innovative Drugs - The innovative drug industry has received significant policy support this year, with the State Council's 2025 strategic goal to create a globally competitive innovation ecosystem [5] - Multiple regulatory bodies have introduced supportive measures, including optimizing review processes and reopening IPO channels for unprofitable companies [6] - The 2024 medical insurance fund expenditure on innovative drugs is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4: Market Dynamics and Future Outlook - By the end of 2024, China is expected to have 3,575 original innovative drugs in clinical trials, surpassing the U.S. and becoming the global leader [7] - The proportion of first-in-class (FIC) drugs has increased from less than 10% in 2015 to 24% in 2024, indicating a significant enhancement in original innovation capabilities [7] - The innovative drug market in China currently accounts for less than 10% of the total pharmaceutical market, indicating substantial growth potential compared to over 20% in other G20 countries [9] Group 5: Investment Opportunities in Innovative Drugs - The China Securities Innovative Drug Industry Index has shown a year-to-date increase of 32.3%, with significant upside potential remaining [8] - The long-term growth of the innovative drug market is supported by an aging population and increasing demand for treatments for chronic diseases and rare diseases [8] - Investing in ETFs that track the innovative drug sector provides a way to mitigate risks associated with individual stock investments while capitalizing on overall industry growth [9]